Nat Med:新型血液检测可提前三年预判阿尔茨海默病

2014-03-12 佚名 新华网

英国新一期《自然—医学》杂志刊登报告说,一种新方法可通过检测血液中的特定脂类含量,来判断早老性痴呆症(又称阿尔茨海默氏症)的风险。新方法最多可提前三年预判这一风险,准确率约为90%。 早老性痴呆症会引发记忆力减退、认知能力下降等,但患者往往只能在这些症状出现后才能确诊,医学界一直在探索能够提前预判患病风险的方法。 美国罗切斯特大学医学院等机构研究人员报告说,他们

英国新一期《自然—医学》杂志刊登报告说,一种新方法可通过检测血液中的特定脂类含量,来判断早老性痴呆症(又称阿尔茨海默氏症)的风险。新方法最多可提前三年预判这一风险,准确率约为90%。



早老性痴呆症会引发记忆力减退、认知能力下降等,但患者往往只能在这些症状出现后才能确诊,医学界一直在探索能够提前预判患病风险的方法。

美国罗切斯特大学医学院等机构研究人员报告说,他们研究发现,血液中有10种脂类的水平与脑细胞膜的完整性密切相关,而后者则可作为早期神经退化的判断依据。他们在试验中抽取了525名70岁以上志愿者的血液样本,并对他们的健康状况进行了5年多的跟踪调查。结果发现,通过分析这10种“生物标记物”可提前2至3年预知痴呆症风险,准确率高达九成。

研究人员说,现有的早期诊断(early diagnosis)方法,比如大脑淀粉样蛋白成像或脑脊液tau蛋白检测等,常需要进行侵入性检测,且耗时长、成本高。新方法在这些方面均具有优势,早老性痴呆症高风险人群可通过这种血检提早判断风险,采取相关措施。

研究人员还表示,发现此类生物标记物的意义不只在于诊断,还可帮助开发有针对性的早期干预或治疗方法,阻止或减缓早老性痴呆症对认知能力等带来的影响。

原始出处:
Mark Mapstone,Amrita K Cheema,Massimo S Fiandaca,Xiaogang Zhong,Timothy R Mhyre,Linda H MacArthur,William J Hall,Susan G Fisher,Derick R Peterson,James M Haley,Michael D Nazar,Steven A Rich,Dan J Berlau,Carrie B Peltz,Ming T Tan,Claudia H Kawas & Howard J Federoff.Plasma phospholipids identify antecedent memory impairment in older adults.Nature Medicine 09 March 2014 doi:10.1038/nm.3466

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1816612, encodeId=e0c71816612a5, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Dec 30 15:58:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879958, encodeId=fd7218e9958d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 09 06:58:00 CST 2014, time=2014-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817635, encodeId=cd7d181e6358e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Apr 22 12:58:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363598, encodeId=baf7136359870, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469989, encodeId=a83e14699892a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606132, encodeId=184c16061324d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1816612, encodeId=e0c71816612a5, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Dec 30 15:58:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879958, encodeId=fd7218e9958d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 09 06:58:00 CST 2014, time=2014-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817635, encodeId=cd7d181e6358e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Apr 22 12:58:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363598, encodeId=baf7136359870, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469989, encodeId=a83e14699892a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606132, encodeId=184c16061324d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
    2014-09-09 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1816612, encodeId=e0c71816612a5, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Dec 30 15:58:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879958, encodeId=fd7218e9958d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 09 06:58:00 CST 2014, time=2014-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817635, encodeId=cd7d181e6358e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Apr 22 12:58:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363598, encodeId=baf7136359870, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469989, encodeId=a83e14699892a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606132, encodeId=184c16061324d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1816612, encodeId=e0c71816612a5, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Dec 30 15:58:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879958, encodeId=fd7218e9958d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 09 06:58:00 CST 2014, time=2014-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817635, encodeId=cd7d181e6358e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Apr 22 12:58:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363598, encodeId=baf7136359870, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469989, encodeId=a83e14699892a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606132, encodeId=184c16061324d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1816612, encodeId=e0c71816612a5, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Dec 30 15:58:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879958, encodeId=fd7218e9958d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 09 06:58:00 CST 2014, time=2014-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817635, encodeId=cd7d181e6358e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Apr 22 12:58:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363598, encodeId=baf7136359870, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469989, encodeId=a83e14699892a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606132, encodeId=184c16061324d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1816612, encodeId=e0c71816612a5, content=<a href='/topic/show?id=17b59e77626' target=_blank style='color:#2F92EE;'>#阿尔茨#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97776, encryptionId=17b59e77626, topicName=阿尔茨)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/Bnia2EtH2IvyBtniaWHPQOYAicsN3IAL1ZuPV7qyALcdCiawRJdEiafMxWTxzERQW7eeKg8HfCKCRK2CJicy073C4RJg/132, createdBy=464b2500186, createdName=ms1948154235210413, createdTime=Tue Dec 30 15:58:00 CST 2014, time=2014-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879958, encodeId=fd7218e9958d7, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 09 06:58:00 CST 2014, time=2014-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1817635, encodeId=cd7d181e6358e, content=<a href='/topic/show?id=4c9f9e777ac' target=_blank style='color:#2F92EE;'>#阿尔茨海#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97777, encryptionId=4c9f9e777ac, topicName=阿尔茨海)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=636e2500187, createdName=12498da4m32(暂无昵称), createdTime=Tue Apr 22 12:58:00 CST 2014, time=2014-04-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1363598, encodeId=baf7136359870, content=<a href='/topic/show?id=40708928907' target=_blank style='color:#2F92EE;'>#血液检测#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89289, encryptionId=40708928907, topicName=血液检测)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=267e204, createdName=wangyang7958, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1469989, encodeId=a83e14699892a, content=<a href='/topic/show?id=45a79e7788c' target=_blank style='color:#2F92EE;'>#阿尔茨海默#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97778, encryptionId=45a79e7788c, topicName=阿尔茨海默)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c5917090900, createdName=yhj-time, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606132, encodeId=184c16061324d, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Mar 14 05:58:00 CST 2014, time=2014-03-14, status=1, ipAttribution=)]

相关资讯

NEJM:阿尔茨海默病新药Solanezumab III期临床试验失败

β-淀粉样蛋白(Aβ)在大脑皮层及海马沉积是阿兹海默氏症的病理改变之一。Solanezumab,一种人源化单克隆抗体,可选择性结合可溶性Aβ,临床前研究表明它能促进大脑Aβ排泄。 为此,礼来(Eli Lilly)开展了Solanezumab 的两项III期临床研究,令人遗憾的是均以失败告终,相关结果发表在2014年1月23日的NEJM上。 该III期临床试验为随机双盲对照研究,以轻到中

EMBO J:阿尔茨海默病防治有突破

最近,有关阿尔茨海默病南开大学沈月全教授课题组获得重要研究进展,其成果近日在线发表在著名国际期刊The EMBO Journal上,这对于阿尔茨海默病的防治和药物设计具重大意义。 沈月全现任南开大学药物化学生物学国家重点实验室副主任和生命科学学院特聘教授,曾担任国家科技部973首席科学家。现在主要研究钙离子信号机理和阿尔茨海默症。 阿尔茨海默病(俗称老年痴呆症)

Neurology:研究发现脉压与阿尔茨海默病生物标记物相关

Fig. 脉压与AD生物学标记物(Aβ1-42, P-tau, P-tau/Aβ1-42)的关联性 血压与认知功能降低及阿尔茨海默病痴呆的关系已得到广泛研究,却少有研究探索血压与认知障碍之间的生物学机制。脉压随年龄呈线性升高,可作为血管衰老的指征之一。脉压已被发现可增加阿尔茨海默病性痴呆的发生风险,但这种关联是完全源于其继发的亚临床性脑血管疾病,或是与阿尔茨海默病的病理生理学存在直接关系

Neurology:皮质铁沉积或为阿尔茨海默病新的影像学标志物

表面铁沉积(SS)是中枢神经系统软脑膜下含铁血黄素沉积的影像学或病理学表现,可通过磁共振T2*或SWI序列检测。皮质SS被认为与脑淀粉样血管病(CAA)以及认知功能障碍相关,既往研究显示CAA患者中皮质SS的发生率为60.5%,无痴呆的老年人群中发生率为0.7%,然而其在阿尔茨海默病(AD)以及其他痴呆类型中的研究较少。【原文下载】 因此,来自荷兰的Frederik

JAMA:西酞普兰与减少阿尔茨海默病患者焦躁有关

据2月19日发表在《美国医学会杂志》上的一则研究披露,药物西酞普兰的使用与减少阿尔茨海默病患者的焦躁不安有关,尽管在该研究中使用的剂量会使病人感到有轻微的认知及心脏方面的不良效应,而这可能会限制患者实际以每天30毫克的剂量服用该药。 根据文章的背景资料,焦躁不安是阿尔茨海默病患者常见的症状,它持续存在、难以治疗且价格昂贵,它还与病人及护理人员的严重不良后果有关。药物治疗已被证明是不够的,而尽

Neurology:阿尔茨海默病脑脊液生物标记物可预测“非认知性”预后

阿尔茨海默病的生物标记物可用于检测“临床前”阿尔茨海默病,而脑脊液中阿尔茨海默病生物标记物(β-淀粉样蛋白42[Aβ42],tau蛋白,181位苏氨酸磷酸化的tau蛋白[ptau181],tau/ Aβ42比值与ptau181/Aβ42比值)是否能在基线时认知功能正常的人群中预测非认知性预后的下降,尚不清楚。为此,来自华盛顿大学医学院Knight阿尔茨海默病研究中心的Catherine M. Ro